These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10363875)

  • 1. Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
    Sundlof DW; Rerkpattanapitat P; Wongpraparut N; Pathi P; Kotler MN; Jacobs LE; Ledley GS; Yazdanfar S
    Am J Cardiol; 1999 Jun; 83(11):1569-71, A7. PubMed ID: 10363875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR
    Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of abciximab after failed thrombolytic therapy.
    Cantor WJ; Kaplan AL; Velianou JL; Sketch MH; Barsness GW; Berger PB; Ohman EM
    Am J Cardiol; 2001 Feb; 87(4):439-42, A4. PubMed ID: 11179529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Blankenship JC; Hellkamp AS; Aguirre FV; Demko SL; Topol EJ; Califf RM
    Am J Cardiol; 1998 Jan; 81(1):36-40. PubMed ID: 9462603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.
    Vahdat B; Canavy I; Fourcade L; Garcia E; Quilici J; Bonnet JL; Bory M
    Catheter Cardiovasc Interv; 2000 Feb; 49(2):177-80. PubMed ID: 10642768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.
    Giri S; Mitchel JF; Hirst JA; McKay RG; Azar RR; Mennett R; Waters DD; Kiernan FJ
    Am J Cardiol; 2000 Aug; 86(3):269-74. PubMed ID: 10922431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Educational program to reduce major bleeding in patients undergoing percutaneous coronary interventions and receiving abciximab.
    Dobesh PP; Lakamp JE
    Am J Health Syst Pharm; 2002 Aug; 59(16):1539-42. PubMed ID: 12185830
    [No Abstract]   [Full Text] [Related]  

  • 10. [Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].
    Gziut AI; Pastwa Ł; Słysz A
    Kardiol Pol; 2006 Mar; 64(3):334-6; discussion 337-8. PubMed ID: 16583343
    [No Abstract]   [Full Text] [Related]  

  • 11. Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator).
    Yaryura RA; Zaqqa M; Ferguson JJ
    Am J Cardiol; 1998 Aug; 82(4):518-9. PubMed ID: 9723644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.
    Khanlou H; Tsiodras S; Eiger G; Abousy K; Goldberg S; Nakhjavan F; Yazdanfar S
    Cathet Cardiovasc Diagn; 1998 Jul; 44(3):313-6. PubMed ID: 9676804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty.
    Joseph T; Marco J; Gregorini L
    Clin Cardiol; 1998 Nov; 21(11):851-2. PubMed ID: 9825202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
    Wong A; Mak KH; Chan C; Koh TH; Lau KW; Lim TT; Lim ST; Wong P; Sim LL; Lim YT; Tan HC; Lim YL
    Catheter Cardiovasc Interv; 2004 Aug; 62(4):445-52. PubMed ID: 15274152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.